UROV Urovant Sciences Ltd.

-0.74  -7%
Previous Close 11.27
Open 11.08
Price To Book 3.12
Market Cap 319300253
Shares 30,322,911
Volume 29,289
Short Ratio
Av. Daily Volume 72,851

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial to be initiated in 2019.
Overactive bladder (OAB)
Phase 2a initiation of enrolment announced January 3, 2019.
Irritable bowel syndrome (IBS)
Phase 3 trial to be initiated 4Q 2018 or 1Q 2019.
Overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH)
Phase 3 data released March 18, 2019 - primary endpoints met. Numerically better than tolterodine but with no p-value.
Overactive bladder (OAB)

Latest News

  1. Here's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data
  2. Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
  3. Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
  4. Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
  5. Urovant Sciences Appoints James Robinson to its Board of Directors
  6. Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript
  7. Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
  8. Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
  9. Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
  10. Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019
  11. Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
  12. Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
  13. Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference
  14. Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference
  15. Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
  16. Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
  17. Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results
  18. Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology
  19. Andreas Halvorsen Discloses Stake in Urovant Sciences